GlassScriptPhysician profile
Sherrie T Eakin
NPI 1184060089
$2,947.45
in general payments reported to CMS, 2019-2025
27 companies · $735 in 2025
The $735 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $230 · 2022: $296 · 2023: $1,030 · 2024: $657 · 2025: $735.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,361 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,360.79 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $803.39 | 2021-2025 | |
| Pfizer INC. | $434.65 | 2023-2025 | |
| Boston Scientific Corporation | $204.40 | 2022-2025 | Intracept, Rezum Generator |
| Astellas Pharma US INC | $198.62 | 2022-2025 | Veozah |
| Astrazeneca Pharmaceuticals LP | $170.42 | 2023-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $154.84 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $135.06 | 2022-2024 | Wegovy, Rybelsus, Ozempic |
| Abbott Laboratories | $134.65 | 2023-2024 | Freestyle Libre 3 |
| Amgen INC. | $86.13 | 2021-2023 | Repatha, Otezla |
| Grifols USA, LLC | $79.69 | 2025 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $70.35 | 2025 | Dupixent |
| Idorsia Pharmaceuticals US INC | $58.75 | 2023-2024 | Quviviq |
| Exact Sciences Corporation | $58.25 | 2023-2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $45.88 | 2023-2024 | Qelbree, Qelbree |
| Baxter Healthcare | $42.51 | 2025 | Hillrom - Vest System Model 105 Home Care |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $38.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.95 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.48 | 2025 | |
| Viatris Specialty LLC | $28.78 | 2025 | Yupelri |
| Ani Pharmaceuticals, INC. | $24.39 | 2025 | Purified Cortrophin Gel |
| Axsome Therapeutics, INC. | $22.93 | 2025 | Auvelity |
| Allergan, INC. | $19.60 | 2021 | |
| Sumitomo Pharma America, INC. | $18.42 | 2023 | Gemtesa |
| Glaxosmithkline, LLC. | $15.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.33 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.76 | 2023 | |
| Esperion Therapeutics, INC. | $12.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherrie Eakin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.